AMEX · RGNT
Healthcare · Medical - Instruments & Supplies
$1.89
Up+$0.01 (+0.26%)
Updated Sep 15, 2026, 12:40 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
RGNT closed at $1.89 after 19 trading sessions, down 7.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.02 | $2.02 | $1.89 | $1.89 | 16.54K |
| Sep 10, 2026 | $2.01 | $2.01 | $1.915 | $1.96 | 12.97K |
| Sep 9, 2026 | $2.06 | $2.07 | $1.98 | $2.01 | 10.49K |
| Sep 8, 2026 | $2.00 | $2.04 | $1.92 | $2.04 | 57.48K |
| Sep 4, 2026 | $1.94 | $2.00 | $1.94 | $1.97 | 16K |
| Sep 3, 2026 | $2.06 | $2.06 | $1.94 | $1.97 | 54.34K |
| Sep 2, 2026 | $2.05 | $2.09 | $2.02 | $2.02 | 14.75K |
| Sep 1, 2026 | $2.04 | $2.11 | $2.005 | $2.06 | 38.49K |
| Aug 31, 2026 | $2.00 | $2.14 | $2.00 | $2.04 | 24.47K |
| Aug 28, 2026 | $2.10 | $2.10 | $2.00 | $2.00 | 19.64K |
| Aug 27, 2026 | $2.12 | $2.12 | $2.06 | $2.06 | 8.34K |
| Aug 26, 2026 | $2.08 | $2.155 | $2.04 | $2.07 | 19.1K |
| Aug 25, 2026 | $2.10 | $2.14 | $2.00 | $2.09 | 19.97K |
| Aug 24, 2026 | $2.15 | $2.18 | $1.96 | $2.16 | 25.65K |
| Aug 21, 2026 | $2.05 | $2.17 | $2.05 | $2.10 | 38.16K |
| Aug 20, 2026 | $2.14 | $2.2199 | $2.06 | $2.06 | 46.03K |
| Aug 19, 2026 | $2.00 | $2.47 | $1.98 | $2.23 | 197.67K |
| Aug 18, 2026 | $1.99 | $2.03 | $1.95 | $1.99 | 51.65K |
| Aug 17, 2026 | $2.04 | $2.0649 | $2.01 | $2.04 | 51.03K |
The latest Smart Investors Daily articles mentioning RGNT.
RGNT research
Company profile and research snapshot.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Aug 28, 2026
Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach...
Benzinga · Jul 20, 2026
Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell
Benzinga · Jul 15, 2026
The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by approximately 400%,
Yahoo · Feb 19, 2026
Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition HERZLIYA, ISRAEL / ACCESS Newswire / February 19, ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RGNT.
No results
No recent SID articles mention RGNT.
